|Bid||31.36 x 800|
|Ask||35.74 x 800|
|Day's Range||33.81 - 36.13|
|52 Week Range||16.74 - 47.00|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||27.90|
|Earnings Date||Feb 21, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.83|
Subscribe to Yahoo Finance Plus to view Fair Value for RCUS
Arcus Biosciences' (NYSE:RCUS) stock is up by a considerable 39% over the past three months. We wonder if and what role...
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.